Tandem Mobi Insulin Pump: Uses, Benefits, and Side Effects

The Tandem Mobi is the smallest insulin pump on the US market — roughly half the size of the Tandem t:slim X2 — and the first US pump to support full bolus dosing from a smartphone app. It is tubed but with very short infusion options (2 to 5 inches) that let the pump body sit directly on the skin. The Mobi runs the same Control-IQ hybrid closed loop algorithm as the t:slim X2 with Dexcom G6 or G7 CGM integration. FDA approved for type 1 diabetes in patients age 6 and older, with strong clinical evidence from the DCLP3 trial.

How the Tandem Mobi Works

• The Mobi pump body adheres to the skin via an adhesive patch with a 2 to 5 inch infusion line to a cannula nearby
• The user can bolus, view trends, and adjust settings from the Tandem t:connect Mobi smartphone app
• An on-body button can also deliver quick boluses without the phone
• Dexcom G6 or G7 sends glucose readings to the Mobi every 5 minutes
• Control-IQ adjusts basal insulin and delivers conservative auto-correction boluses (up to once per hour) based on predicted glucose
• The reservoir holds 200 units and is changed every 3 days
• The pump body recharges wirelessly on an inductive charging pad

Components and Specifications

Control-IQ Algorithm

Control-IQ is Tandem’s hybrid closed loop algorithm, shared between the t:slim X2 and Mobi. Key features:

• Reads Dexcom CGM glucose every 5 minutes
• Predicts glucose 30 minutes ahead
• Increases basal when glucose is predicted above 160 mg/dL
• Decreases or suspends basal when glucose is predicted below 80 mg/dL
• Delivers conservative auto-correction bolus when glucose is predicted above 180 mg/dL and rising (max once per hour, 60 percent of calculated correction)
• Sleep activity — tighter target range 112.5 to 120 mg/dL overnight; no auto-corrections (smoother sleep)
• Exercise activity — higher target 140 to 160 mg/dL during workouts; reduced auto-corrections

Smartphone-Only Bolusing

The Mobi (with 2024 FDA approval) is the first US pump to support full bolus calculation and delivery from a smartphone. This is a meaningful change because:

• Users no longer need to retrieve the pump from under clothing to bolus
• The phone provides a larger screen for carb entry and trend display
• Bluetooth lock ensures only the user’s phone can bolus
• Bolus from phone integrates seamlessly with food logging apps in some integrations
• The on-body button remains available as backup

DCLP3 Trial — Clinical Evidence

The Diabetes Control to Lower Pediatric Glucose (DCLP3) trial (Brown et al., NEJM 2019) studied 168 patients age 14 to 71 with type 1 diabetes randomized to Control-IQ on t:slim X2 vs sensor-augmented pump (no automation) for 6 months:

• Time in Range (70 to 180 mg/dL) improved from 61 percent baseline to 71 percent on Control-IQ
• Sensor-augmented pump group remained at 59 percent (no significant change)
• Mean glucose dropped 13 mg/dL
• A1C improved 0.33 percentage points
• Hypoglycemia (below 70 mg/dL) decreased significantly
• No diabetic ketoacidosis or severe hypoglycemia attributable to system

The Mobi inherits this evidence base since the algorithm is identical to that tested in DCLP3.

Comparison with Other AID Systems

Benefits

• Smallest tubed pump on US market — discreet under clothing
• Full smartphone bolus — most modern user experience
• Short tubing option — patch-like wear with traditional tubed reliability
• Control-IQ proven — DCLP3 evidence base
• Dexcom G7 compatibility — newest small-form CGM
• Sleep and exercise activities — better overnight and workout glucose control
• Wireless charging — no charging port to fail or attract moisture
• Waterproof — IPX8 rated

Drawbacks and Considerations

• 200-unit reservoir — high-dose users may need to refill before 3 days
• Tubed (not tubeless) — even short tubing is tubing
• Battery charging routine — requires weekly recharge habit
• Fixed 112.5 mg/dL target — less flexibility than Omnipod 5’s adjustable targets
• Conservative auto-corrections — less aggressive than Medtronic 780G’s hourly corrections
• Dexcom required — no Abbott Libre support
• Tubing placement — short tubing limits where pump can sit relative to cannula

Site and Wear

• The Mobi pump body adheres to skin via an adhesive patch
• The cannula site changes every 3 days; the pump body can be moved as needed
• Rotate cannula sites among abdomen, upper outer thigh, upper buttocks, and upper outer arm
• Inspect site daily for redness, leakage, or tenderness
• Use barrier wipes or overlay tape if adhesion is a problem
• The short tubing (2 inches) is the most discreet but limits cannula placement to within reach of pump body

Side Effects and Risks

• Diabetic ketoacidosis — risk if cannula occludes or pump body dislodges
• Hypoglycemia — reduced vs MDI; Control-IQ is conservative compared to 780G
• Infusion site reactions — common to all pumps
• Adhesive reactions — itching, rash; barriers help
• Battery failure — rare; backup MDI plan required
• Phone failure — pump remains functional via on-body button
• Algorithm exits to manual mode — if CGM signal lost

Cost and Insurance

Medicare Part B covers the Mobi and supplies under durable medical equipment. Commercial insurance typically covers under DME with prior authorization. Tandem offers a financial assistance program for eligible patients.

Related Reading

For pump fundamentals see how does an insulin pump work. Compare with other AID systems in our Omnipod 5 and Medtronic 780G guides, or read the broader hybrid closed loop systems overview. For broader context see insulin therapy and all treatment options.

External Resources

The FDA medical device database contains Tandem Mobi approval documentation, and the American Diabetes Association Standards of Care 2024 covers AID systems and pump prescribing.

The Bottom Line

The Tandem Mobi is the smallest insulin pump on the US market and the first US pump approved for full bolus control from a smartphone. It is technically tubed but with infusion options as short as 2 inches, letting the pump body sit directly on the skin like a patch pump. The Mobi runs the same Control-IQ hybrid closed loop algorithm as the larger t:slim X2 — proven in the DCLP3 trial to improve Time in Range and reduce hypoglycemia — paired with Dexcom G6 or G7 CGM. Strengths include the compact size, modern phone-first interface, sleep and exercise modes, and waterproof rating. Drawbacks include the 200-unit reservoir for high-dose users, the fixed 112.5 mg/dL glucose target, and the Dexcom-only CGM requirement. FDA approved for type 1 diabetes age 6 and older. Talk to your endocrinologist about whether the Mobi’s small size and full phone control fit your daily routine.